Sumary of Monoclonal antibody therapy for COVID-19 safe, effective for transplant patients, study finds:
- Treating transplant patients with mild to moderate cases of COVID-19 with monoclonal antibodies is safe and helps prevent serious illness, according to a Mayo Clinic study recently published in Open Forum Infectious Diseases..
- These results are especially important because transplant patients who are infected with COVID-19 have a higher risk of severe illness and death..
- “Monoclonal antibody therapy is really important for the transplant population because they are less likely to develop their own immunity..
- The retrospective study focused on the first 73 solid organ transplant patients who received monoclonal antibody infusions for treatment of mild to moderate COVID-19 between Nov..
- “While we expected monoclonal antibody therapy would be beneficial for patients, we were pleasantly surprised by the results..
- In fall 2020, the Food and Drug Administration authorized the emergency use of bamlanivimab and casirivimab-imdevimab to treat mild to moderate COVID-19 in patients with a high risk of becoming seriously ill..
- But since the safety and efficacy of these therapies for transplant patients remained unknown due to the limited clinical data, many health care institutions initially hesitated to set up infusion centers, Dr. Razonable says..
- The study’s results highlight the important role monoclonal antibodies can play in treating transplant patients with mild to moderate COVID-19….